Oral melphalan as a treatment for platinum-resistant ovarian cancer

British Journal of Cancer

Volumn 88, Issue 12, 2003, Pages 1828-1830

  Hasan, J ^a   Jayson, G C ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Alkylating agents; Ovary; Second line

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; MELPHALAN; OXALIPLATIN; PACLITAXEL; TAXANE DERIVATIVE; TOPOTECAN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW DEPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG MONITORING; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; THROMBOCYTE TRANSFUSION; TUMOR RECURRENCE;

ADMINISTRATION, ORAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MELPHALAN; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0038236563     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601044     Document Type: Article

References (11)

1. Blackledge G, Lawton F, Redman C, Kelly K (1989) Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and design of phase II trials. Br J Cancer 59: 650 - 653
2. Brodovsky HS, Bauer M, Horton J, Elson PJ (1984) Comparison of melphalan with cyclophosphamide, methotrexate and 5-fluorouracil in patients with ovarian cancer. Cancer 53: 844 - 852
3. Gore M (2001) Treatment of Relapsed Epithelial Ovarian Cancer, pp 468 - 476, ASCO Educational Book Spring. Lippincott Williams and Wilkins, Philadelphia
4. Greenlee RT, Hill-Harmon MB, Murray T, Thun M (2001) Cancer statistics, 2001. CA: Cancer J Clin 51: 15 - 36
5. Klaassen D, Shelley W, Starreveld A, Kirk M, Boyes D, Gerulath A, Levitt M, Fraser R, Carmichael J, Methot Y (1988) Early stage ovarian cancer: a randomised clinical trial comparing whole abdominal radiotherapy, melphalan and intraperitoneal chromic phosphate: a National Cancer Institute of Canada Clinical Trials Group report. J Clin Oncol 6: 1254 - 1263
6. Markman M, Reichman B, Hakes T, Rothman R, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis Jr J (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9: 389 - 393
7. Meyer T, Nelstrop AE, Mahmoudi M, Rustin GJ (2001) Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer. Ann Oncol 12: 1705 - 1709
8. Pater JL, Carmichael JA, Krepart GV, Fraser RC, Roy M, Kirk ME, Levitt M, Brown LB, Wilson KS, Shelley WE (1987) Second-line chemotherapy of stage III-IV ovarian carcinoma: a randomised comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin. Cancer Treat Rep 71: 277 - 281
9. van der Burg ME, de Wit R, van Putten WL, Logmans A, Kruit WH, Stoter G, Verweij J (2002) Weekly cisplatin and daily oral etoposide is highly effective in platinum pre-treated ovarian cancer. Br J Cancer 86: 19 - 25
10. Wadler S, Yeap B, Vogl S, Carbone P (1996) Randomised trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results - Eastern Cooperative Oncology Group Study E2878. Cancer 77: 733 - 742
11. Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, Miller A, Park R, Major Jr F (1990) Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomised trials. N Engl J Med 322: 1021 - 1027